MANUFACTURING ARTICLES
-
Comparing Advanced Modality Needs, Part 2: Regulatory And Market Access
ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics differ considerably in regulatory requirements, commercial viability, and implications for delivery.
-
Scaling Personalization: Inside The Manufacturing & Analytical Hurdles Of mRNA Cancer Immunotherapies
As we know from the autologous cell therapies that have come before us, manufacturing and scaling personalized products is no mean feat, and there are a handful of efforts we need to be tackling today to realize a more efficient and (ideally) decentralized manufacturing process. Fortunately for us, the panel had a few ideas on what it will take to make our analytical development and manufacturing more efficient processes.
-
The Hidden Biology Of RNA Impurities: When Manufacturing Changes Therapeutic Behavior
Two mRNA batches may contain the same intended therapeutic sequence yet produce different biological responses. One explanation lies in the unintended RNA species generated during manufacturing.
-
Comparing Advanced Modality Needs, Part 1: Manufacturing
ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.
-
Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions
This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.
-
Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing
Let's delve into manufacturing strategy, conjugation chemistry, process development and scale-up, and purification: the central manufacturing challenge.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.
-
Discover how osmolality can be applied throughout the bioprocessing workflow for RNA, and recognize the importance of this sensitive measurement, from formulation optimization to cryopreservation techniques.
-
Explore scalable processes for lentiviral vector production and clarification at the 50 L scale, utilizing the CTS LV-MAX system and single-use bioreactors for robust gene therapy manufacturing.
-
A two-dimensional LC/MS strategy improves the separation of coeluting oligonucleotide impurities. High-resolution sampling and automation enable deeper characterization of low-level variants.
-
Learn best practices for high-resolution analysis of IVT RNA using automated capillary electrophoresis. Improve accuracy and precision in quantifying critical quality attributes.
-
This overview outlines regulatory guidelines for sampling, examines the limitations of conventional methods, and emphasizes the advantages of aseptic, single-use approaches in achieving compliance.
-
Prioritize operational efficiency over early-stage flexibility to scale advanced therapies. Standardized workflows and qualified shipping lanes reduce variability for predictable late-phase success.